

## **Requirements for Successful Completion of PGY2 Oncology Residency**

### **Participation in Residency Orientation Program**

A formal orientation program for residents is scheduled at the beginning of the program. The resident is expected to complete all orientation activities. This orientation period is used to introduce the incoming residents to the Departments of Pharmacy, Clinical Pharmacy Services, Antimicrobial Stewardship Program, and to outline the expectations for the residency year.

### **Completion of all Required and Elective Learning Experiences**

### **Achievement of PGY2 Oncology Residency Learning Objectives**

For successful completion of the residency, the resident MUST have “Achieved” the learning objectives associated for ALL goals, as assessed by the PGY-2 steering committee. Verbal comments from preceptors and evaluations of the resident learning experiences will be used by the steering committee to determine whether or not the resident has earned a “Satisfactory Progress” or “Achieved” on an objective. This assessment will occur on a monthly basis. Should the Steering Committee determine that the resident has “Achieved” a learning objective, the objective will continue to be evaluated throughout the residency, so that the resident can benefit from additional preceptor comments.

### **Preparation of a Manuscript Acceptable for Publication**

The resident is required to write at least one manuscript suitable for publication in a peer-reviewed biomedical journal. This manuscript may include a drug monograph, journal article, case report, etc. The topic of this written work will be determined by the resident and his/her residency program director based on the resident's background, experience and goals. Editorial assistance by a preceptor is required. The resident must be first author and responsible for submission and revisions to a journal. The resident must submit a manuscript for publication within 6 months of graduation or risks losing primary authorship.

### **Active Participation in the Successful Completion of a Medication Use Evaluation**

The resident is required to participate in a Medication Use Evaluation (MUE). MUEs will be performed in conjunction with the Residency Program Director and/or the Drug Information Center Preceptor. Satisfactory performance as determined by the Residency Program Director and/or Drug Information Center Preceptor is required for successful completion of the program.

### **Successful Completion of a Major Residency Project**

The resident is required to participate in a longitudinal project. The resident will collaborate with pharmacy preceptors and any collaborators to identify, design, execute and report the results of an infectious diseases pharmacy practice research project. In addition, the resident is required to attend all ambulatory subsection of PRIME (Pharmacy Research Institute for Medication Use and Effectiveness) meetings. Satisfactory performance as determined by the Residency Program Director and/or project preceptors is required for successful completion of the program.

### **Presentation of a Resident Continuing Education Program**

The resident will present one continuing education program during the residency program. The goal of the presentation is to improve the resident's communication skills and techniques, literature evaluation, and understanding of the continuing education process. The seminar topic will be selected by the resident with guidance from at least one preceptor (selected by the resident), and should involve a therapeutic or practice management controversy, developing clinical or practice management research, or therapeutic area.

### **Participation in Residency Advisory Committee Meetings**

The resident will attend quarterly Resident Advisory Committee meetings to report on progress in residency activities to the committee.

### **Participation in Henry Ford Hospital Multi-Disciplinary Committee Meetings**

The resident will participate in selected hematology/oncology subcommittee of P&T meetings. The resident is required to prepare and present at minimum one drug monograph for approval during the residency year.

### **Participation in Multidisciplinary Education**

- The resident will participate in weekly resident/student pharmacy grand rounds
- The resident will routinely participate in weekly hematology/oncology didactic sessions
- The resident will complete at least one formal in service to nursing or physician staff
- Complete at least one lecture to the Hematology/Oncology fellows or journal club at senior staff meeting.

### **Attendance and Presentation at the HOPA Annual Conference**

The HOPA Annual Conference is held in the spring and is a forum where oncology clinical specialists and residents attend to share their expertise in the field of oncology. The resident will prepare and present their major residency project at the resident poster session at the conference. The resident will be evaluated by HOPA members during the session.

### **Attendance and Presentation at the Great Lakes Residency Conference**

The Great Lakes Residency Conference is held in the spring and is a forum where residents share experiences and expertise. The resident will make a brief presentation on their project or MUE which will be evaluated by a preceptor outside of the program.

### **Participation in Transitions of Care (TOC) consults**

The PGY2 oncology resident is required to participate in pharmacy TOC consults while on acute care/inpatient rotations.

*Goal R1.2 (and associated objectives): Ensure continuity of care during transitions on oncology patients between care settings.*

### **PGY2 Resident TOC Consult Requirements**

| <b>Quarter 1</b> | <b>Quarter 2</b> | <b>Quarter 3</b> | <b>Quarter 4</b> |
|------------------|------------------|------------------|------------------|
| 12               | 22               | 30               | 36               |

The resident is responsible for tracking their own consult progress and notifying each rotation preceptor of their TOC consult progress. Resident progress towards consult independence will be discussed at monthly RAC meetings and documented in Pharm Academic. If a resident fails to meet the competency requirement, the resident's advisor will work with the resident to develop a customized plan. PGY2 oncology independence will be determined by the RPD and TOC coordinator.

### **Planning and Execution of Pharmacy Community Event**

The resident is required to plan and execute a community event in the residency year that promotes the wellness and benefit of oncology patients and caregivers. The event will be coordinated exclusively by the resident in conjunction with the RPD and community event coordinator.

For the PGY2 Hematology/Oncology Residency, the following definitions will be used in evaluating resident progress:

**Needs Improvement (NI)** – Resident performance could potentially result in patient harm or an unfavorable impression of the profession of pharmacy within the institution.

**Satisfactory Progress (SP)** – Resident performance is at an appropriate level; however, the resident is not yet ready to perform the objective independently.

**Achieved (ACH)** – PGY2 resident is performing practice skills independently, consistently, and skill level is approaching that of the preceptor.